心通医疗(02160.HK)预告上半年收入增加22%-28%

阿斯达克财经07-05

心通医疗－Ｂ(02160.HK) 公布，预计6月止六个月收入介乎2.15亿至2.25亿人民币，按年增加22%-28%。主要因经导管主动脉瓣植入术产品在内地的入院持续进展推动产品植入量和配件产品使用量增长，带来收入增加；附属上海佐心自主研发的AnchorMan在内地正式开启商业化进程，为集团贡献增量收入；及经导管主动脉瓣膜及输送系统和球囊扩张导管期内在俄罗斯和智利等国的商业化带来的海外收入快速增长。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449420276?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220906143936150_s.jpg","is_english":false,"pubTime":"2024-07-05 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449420276","market":"us","top_or_hot":-1,"title":"心通医疗(02160.HK)预告上半年收入增加22%-28%","media":"阿斯达克财经","content":"<div>\n<p>心通医疗－Ｂ(02160.HK) 公布，预计6月止六个月收入介乎2.15亿至2.25亿人民币，按年增加22%-28%。主要因经导管主动脉瓣植入术产品在内地的入院持续进展推动产品植入量和配件产品使用量增长，带来收入增加；附属上海佐心自主研发的AnchorMan在内地正式开启商业化进程，为集团贡献增量收入；及经导管主动脉瓣膜及输送系统和球囊扩张导管期内在俄罗斯和智利等国的商业化带来的海外收入快速增长。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361472/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通医疗(02160.HK)预告上半年收入增加22%-28%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通医疗(02160.HK)预告上半年收入增加22%-28%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 01:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361472/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>心通医疗－Ｂ(02160.HK) 公布，预计6月止六个月收入介乎2.15亿至2.25亿人民币，按年增加22%-28%。主要因经导管主动脉瓣植入术产品在内地的入院持续进展推动产品植入量和配件产品使用量增长，带来收入增加；附属上海佐心自主研发的AnchorMan在内地正式开启商业化进程，为集团贡献增量收入；及经导管主动脉瓣膜及输送系统和球囊扩张导管期内在俄罗斯和智利等国的商业化带来的海外收入快速增长。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361472/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361472/latest-news/AAFN","article_id":"2449420276","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220906143936150_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449420276","pubTimestamp":1720113300,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"心通医疗－Ｂ公布，预计6月止六个月收入介乎2.15亿至2.25亿人民币，按年增加22%-28%。期内，集团严格执行成本管控措施，提升运营效率，致力在保持收入稳步增长的前提下尽快实现盈亏平衡。沽空资料截至 2024-07-04 16:25。)过往派息公布日期派息事项派息内容2024/03/27末期业绩无派息2023/08/29中期业绩无派息2023/03/29末期业绩无派息 2022/08/29中期业绩无派息 AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1100":"医疗保健设备","BK1583":"高瓴概念","02160":"心通医疗-B"},"translate_title":"Xintong Medical (02160. HK) forecasts a 22%-28% increase in revenue in the first half of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1},"content_text":"心通医疗－Ｂ(02160.HK) 公布，预计6月止六个月收入介乎2.15亿至2.25亿人民币，按年增加22%-28%。主要因经导管主动脉瓣植入术产品在内地的入院持续进展推动产品植入量和配件产品使用量增长，带来收入增加；附属上海佐心自主研发的AnchorMan在内地正式开启商业化进程，为集团贡献增量收入；及经导管主动脉瓣膜及输送系统和球囊扩张导管期内在俄罗斯和智利等国的商业化带来的海外收入快速增长。期内，集团严格执行成本管控措施，提升运营效率，致力在保持收入稳步增长的前提下尽快实现盈亏平衡。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-04 16:25。)过往派息公布日期派息事项派息内容2024/03/27末期业绩无派息2023/08/29中期业绩无派息2023/03/29末期业绩无派息 2022/08/29中期业绩无派息 AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449420276"}